Sorouks to Change Name to "ARI ONE," Accelerating Transition to Global Bio Platform

Sorouks is accelerating its transition to a global bio platform company by changing its company name to "ARI ONE."

The company announced on May 21 that it will propose the name change as an agenda item at an extraordinary general meeting of shareholders to be held on June 29. The new name, ARI ONE, is expected to serve as an integrated growth platform, connecting AI, data centers, and advanced infrastructure businesses around its core growth engines: ARIBIO, an innovative drug development company, and ARIBIOLAB, a vaccine platform company.

ARIBIO has entered the final stage of global Phase 3 clinical trials with its Alzheimer's treatment, AR1001. Recently, the company signed a technology export contract worth approximately 7 trillion won with the Chinese pharmaceutical company Fuxing Pharmaceutical, demonstrating its global business potential. The company expects that the confirmed early receipt of the upfront payment and option fees will serve as an opportunity to showcase the business competitiveness of AR1001 and the feasibility of the contract to the market.

ARIBIOLAB is working to expand its vaccine platform technology into the prevention and treatment of degenerative brain diseases. The company explained that if the AR1001 treatment and the preventive vaccine platform are combined in the future, ARI ONE could grow into a full-cycle solution platform encompassing both treatment and prevention of dementia.

The company also actively addressed concerns in the market regarding the 30 billion won convertible bond (CB) issue that was recently raised. A company representative stated, "This CB is not a simple standalone investment, but a joint investment structure with financial institutions and major investors participating. The payment process is proceeding smoothly, so market concerns will naturally be resolved."

The representative added, "A 50% call option has been set on the CB, which sufficiently ensures management stability. The scenario of a change in the largest shareholder, as some have suggested, is realistically highly unlikely."

The company emphasized that this name change is not just an image makeover, but represents a shift in its mid- to long-term business strategy. The representative said, "This decision reflects our commitment to building a global bio platform centered on ARIBIO and ARIBIOLAB. Based on the global achievements of AR1001 and the early inflow of proceeds from the technology export contract, we will present the market with a new growth structure that connects therapeutics, vaccines, AI, and data centers."

Industry insiders see Sorouks' name change and restructuring of its business model as a signal that the company is fully embracing a bio-centered growth strategy.

This content was produced with the assistance of AI translation services.